CEO, I-Mab Biopharma
Dr. Shen is a US board-certified physician and holds a PhD in life sciences from Indiana University School of Medicine, where she was appointed as an adjunct professor in the department of psychiatry. She also completed fellowships in endocrinology, psychopharmacology and clinical pharmacology. Her scientific contributions have led to multiple research grant awards and more than 30 publications.
Dr. Shen’s pharmaceutical career began at Eli Lilly & Company, after which she held executive positions at Wyeth, Pfizer, Jiangsu Hengrui Medicine and Johnson & Johnson. She was the clinical head at Pfizer China and the Chief Medical Officer at Jiangsu Hengrui Medicine, where she built the largest clinical team among Chinese domestic pharma companies and established successful clinical trials in China, the US and Australia. At J&J, Dr. Shen served as China Development Head and oversaw all clinical development programs in China, including multiple innovative drugs that were approved by China NMPA, such as Sirturo, Olysio, Imbruvica, Simponi, and Stelara.
Dr. Shen serves as co-chair of the R&D-based Pharmaceutical Association in China’s (RDPAC) core R&D team, sits on the China New Drug Research Evaluation Executive Committee, and is currently a guest professor at the Beijing University Clinical Research Institute.